Vaccines: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry

    Published: April 1, 2008 | Price: $995.00 – $8,200.00

    Few areas of pharmaceuticals have seen the fast-moving developments in the marketplace that the vaccine market has in 2007 and 2008. Since Kalorama Information last updated Kalorama Information's The World Market for Vaccines in the first quarter of last year, new products and better than expected profits have transformed the vaccine marketplace. Approvals that have been granted for products such as RotaTeq, Pentacel, Adacel and Zostavax and FluMist are now impacting the market. The launch and execution of the first...
    World Market for Prescription Generic Drugs, 6th Edition

    Published: April 1, 2008 | Price: $995.00 – $7,990.00

    Generics, so long the force that has shaken up the branded pharmaceutical industry, is now facing its own challenges as an industry. While growth indications are strong, there are challenges for generic companies. In the next two years, consolidation will most likely rise; the sector is expected to be rocked by increased competition from companies in Eastern Europe, India and China, as well as brand name companies seeking to protect their franchises by moving into generics. Kalorama Information's World Market...
    Biogenerics: The World Market for Biosimilars

    Published: April 1, 2008 | Price: $995.00 – $7,000.00

    In one sense, the opportunity for follow-on proteins is as good as ever. Some of the biggest-selling biologics developed during the first phase of the biotechnology revolution in the 1980s, including human growth hormone (hGH) and insulin, have lost patent protection or are set to lose patent protection in the US in 2007 and beyond. But there are also regulatory challenges to marketing follow-on biologics in the U.S. that companies will need to navigate to prosper. In this report, Biogenerics:...
    Key Topics in Pharmaceutical Market Strategy 2008 (Drug Pricing, Rx to OTC switches, Retail Clinics, Prescribing Pharmacists, The Growing Out of Pocket Healthcare Market)

    Published: March 15, 2008 | Price: $6,995.00 – $13,990.00

    Pharmaceutical marketers will face a challenging time in 2008 by all reports. Understanding the dynamics of the market can assist in better planning and strategy. This Kalorama Information Report Bundle combines 5 of the most important topics for those in the pharmaceutical industry in a strategic planning, business development or marketing. Grouped together, this report reprsents over 60% off the individual report price. Retail Clinics These entities may change how America gets healthcare, and may become important outlets for pharmaceutical...
    RFID in Pharmaceutical Manufacturing: Cost Saving Strategies for Pharmaceutical Companies and Opportunities for Technology Companies

    Published: March 1, 2008 | Price: $995.00 – $3,990.00

    Pharmaceutical manufacturers are utilizing new RIFD technologies to deal with multiple challenges they face in the manufacturing process. This Kalorama Information report discussions the solutions available, and covers the opportunities available to technology companies to provide services to this sector. Full coverage of the market for RFID technologies in pharmaceutical manufacturing operations is provided, including.   Explanation of RFID Technologies Cost Savings from Implementation Total Market for RFID Technologies in Pharma Manufacturing Market Forecasts Major Companies Involved in RFID and...
    Pharmaceutical Excipients for Oral Formulations, 2nd. Edition

    Published: February 1, 2008 | Price: $995.00 – $7,990.00

    Pharmaceutical excipients are substances, other than the pharmacologically active drug or prodrug, which are included in the manufacturing process or are contained in the finished pharmaceutical product dosage form. Excipients provide enhanced functionality to the pharmaceuticals, aid the innovations in the drug development and help improve patent life as well. Excipients make the products more functional at a lower cost, a benefit much desired by the pharmaceutical industry that is inundated with pressures to reduce costs. All in all, excipients...
    Congestive Heart Failure – Major World Markets, Volume I – Pharmaceutical Management

    Published: February 1, 2008 | Price: $895.00 – $6,990.00

    Congestive heart failure is an increasingly important cause of cardiovascular morbidity and mortality. It is the number one cause of hospitalization among individuals aged 65 and over. The United States Medicare system pays out more for the care of congestive heart failure than it does for all forms of cancer combined. While this is a challenge for the US healthcare system, it indicates a strong market opportunity for pharmaceutical companies involved in CHF treatment. Kalorama Information's Congestive Heart Failure, Major...
    Prescription Dermatological Drugs: Worldwide Market, 6th Edition

    Published: January 1, 2008 | Price: $4,200.00 – $7,800.00

    One of Kalorama's best-selling market research reports, this report provides the reader with a complete analysis of the domestic and international markets for pharmaceuticals to treat skin diseases and disorders. This edition of Worldwide Market for Prescription Dermatological Drugs is the sixth time Kalorama Information has comprehensively studied the dermatology markets. Kalorama has completely re-evaluated the market from the ground up, and in addition to the usual primary research (interviews) of industry participants, clinicians, and regulators, we also conducted scores...
    Pediatric Drugs: the Worldwide Market, 3rd Edition

    Published: January 1, 2008 | Price: $995.00 – $7,990.00

    Although much of medicine is focused on the increased aging of the population, children still represent the bulk the dependent population worldwide. Important regulatory factors are at work in the pediatric pharmaceutical market. The recognition of the rights of children to have access to safe and effective drugs and the needs of healthcare providers to have access to age-appropriate drug information continues to have a major effect on all areas of pediatric pharmaceuticals including pediatric biomedical research. Pediatric Drugs, the...
    Worldwide Market for Rheumatoid Arthritis and Lupus Treatments ( Autoimmune Disease Markets )

    Published: January 1, 2008 | Price: $995.00 – $7,000.00

    Rheumatoid arthritis and lupus belong to a number of autoimmune diseases affecting the musculoskeletal system, multisystemic tissue, and connective tissues. Although a range of autoimmune conditions carry a low prevalence, combined these diseases amount to a growing medical and economic burden. Additionally, autoimmune diseases are accounting for a growing cause of disability in the United States, Europe and worldwide. Kalorama's Worldwide Market for Rheumatoid Arthritis and Lupus Treatments (Autoimmune Disease Markets) is the most comprehensive look at the markets for...
    World Cardiovascular Drug Market, (Antihypertensives, Antihyperlipidemics, Vasodilators, Anticoagulants, Diuretics and other Agents) , The

    Published: December 1, 2007 | Price: $995.00 – $7,990.00

    Kalorama's 2nd edition of The World Cardiovascular Drugs Market, in its 2nd edition, will steer marketers through the sheer size and diversity of the current market and the potential of new products that will make this therapeutic category among the most competitive of prescription drug segments. Analyst Mary Ann Crandall considers both the exisiting products and the pipeline in this comprehensive market study. The following market segments are covered: Cardiac Glycosides and Positive Inotropic Agents Antihypertensive Agents (ACE Inhibitors, Angiotensin...
    Offshoring Clinical Trials (The Market for Clinical Trials in India, China, Mexico, Brazil, Russia and Israel.)

    Published: November 1, 2007 | Price: $1,500.00 – $7,000.00

    Offshoring of clinical trials is increasing as companies in the U.S. are finding challenges in clinical trial research ranging from cost, patient recruitment, patient compliance during participation, qualified professionals, new clinical trial patients, and other problems. This provides an opportunity for BRIC countries and other developing regions to grab a piece of the clinical trial market. Countries such as India and China have a vast population who are interested in taking part in clinical trial research, and these regions can...
    Prescribing Pharmacists: A Decision Maker Emerges

    Published: October 1, 2007 | Price: $995.00 – $5,000.00

    In five years, Kalorama Information believes that given the role of pharmacists currently and the demands of the US healthcare system, pharmacists will be prescribing in at least six states in five years, creating a trend that will spread to many other states in following years. The state of Florida allows some independing prescribing off an approved list, and many states allow prescription choice from a physicians diagnosis. The cost of copays and the time spent on doctor visits will...
    Drug Pricing and Reimbursement Strategies: Preparing for the Coming Generic Onslaught

    Published: October 1, 2007 | Price: $995.00 – $1,990.00

    It can be said that pharmaceutical companies face a 'new era.' in the coming years. Old strategies will not produce the same results. A wave of generic competition is poised to affect most brands. Drug companies have had to cut research budgets, leading to a dearth of new products on the market. This means there is very little margin for error in the pricing decision. Drug pricing is one of the key levers that determine the profitability of a drug...
    Global Hepatitis Treatment and Diagnostics

    Published: August 1, 2007 | Price: $995.00 – $1,990.00

    The unrecognized importance, danger and costs of hepatitis in the 21st century cannot be understated or underestimated. The impact of the disease on world society is highly significant and now presenting a major crisis in public health circles. In his exhaustive analysis of the potential diagnosis, screening and therapeutic markets for hepatitis, Ken Krul, PhD. advises companies to think on a global basis. In this study, Global Hepatitis Strategies Krul examines the potential market, epidemiology (hepatitis patient trends) and technology...